Novartis C.E.O. Defends Company ’s Decision to Withhold False Data From the F.D.A.

Responding to the agency ’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Novartis AG Narasimhan, Vasant Food and Drug Administration Zolgensma Falsification of Data Drugs (Pharmaceuticals) Genetic Engineering Spinal Muscular Atrophy Source Type: news